Immunoglobulin G4 related disease: a single‐centre experience from South Australia

Background IgG4 related disease (IgG4RD) is a newly described multisystem fibro‐inflammatory disorder. There is a paucity of literature describing the Australian experience of this rare condition. Aims To characterise the Royal Adelaide Hospital IgG4RD cohort with biopsy‐proven disease. Methods A se...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Internal medicine journal 2019-09, Vol.49 (9), p.1099-1104
Hauptverfasser: Pucar, Phillippa A., Nolan, James, Hissaria, Pravin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1104
container_issue 9
container_start_page 1099
container_title Internal medicine journal
container_volume 49
creator Pucar, Phillippa A.
Nolan, James
Hissaria, Pravin
description Background IgG4 related disease (IgG4RD) is a newly described multisystem fibro‐inflammatory disorder. There is a paucity of literature describing the Australian experience of this rare condition. Aims To characterise the Royal Adelaide Hospital IgG4RD cohort with biopsy‐proven disease. Methods A search of the Frome Road SA Pathology database was performed for all tissue biopsies containing the phrase ‘IgG4 positive’. Case notes were reviewed for clinical details, laboratory and radiology results. Histological features according to the Boston Criteria were used. Patients with available case notes, highly suggestive or probable histology and clinical features to suggest IgG4RD were included. Results Twenty patients had definite or probable IgG4RD and suggestive clinical features; median age 59 (20–76), male : female 1.5:1. There was considerable delay in diagnosis (median diagnosis at 64 months). Organ involvement included: 11 exocrine gland, seven pancreatobiliary, seven nodal, seven soft tissue, five retro‐orbital, three retroperitoneal fibrosis and two renal. Systemic symptoms at diagnosis were seen in eight patients. Seven (35%) had an elevated serum IgG4 (>1.35 g/L) at diagnosis. Only 12 (60%) required immunosuppressive treatment (corticosteroids); of these, four (20%) required a steroid‐sparing agent and four (20%) required B‐cell depleting therapy (rituximab). The median duration of follow up was 18 months. Conclusions This is the first characterised Australian cohort with generalised IgG4RD, a rare, relatively indolent and under‐recognised multisystem disorder. Diagnosis is difficult given lack of awareness of this rare condition among physicians, its presentation as a great disease mimic, challenges with histopathological assessment and the absence of a suitable serum biomarker.
doi_str_mv 10.1111/imj.14331
format Article
fullrecord <record><control><sourceid>proquest_wiley</sourceid><recordid>TN_cdi_proquest_miscellaneous_2232115722</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2232115722</sourcerecordid><originalsourceid>FETCH-LOGICAL-p1711-cce514bb01b2d5cddcd9d3f6fb164b294138ec7008f84b42fff1760f89caf0da3</originalsourceid><addsrcrecordid>eNpdkLFOwzAURS0EEqUw8AeWWFjS-sVOk7BVFZSiIgbKHDn2c3HlJMVOBN34BL6RLyEtTLzl3uHo6ukQcglsBP2NbbUZgeAcjsgAhEiiJM_F8aGLiOWMn5KzEDaMQcpzMSCrRVV1dbN2Tdk5W9O5oB6dbFFTbQPKgDdU0mDrtcPvzy-FdeuR4scWvcVaITW-qehz07WvdNqF1ktn5Tk5MdIFvPjLIXm5u13N7qPl03wxmy6jLaQAkVKYgChLBmWsE6W10rnmZmJKmIgyzgXwDFXKWGYyUYrYGAPphJksV9IwLfmQXP_ubn3z1mFoi8oGhc7JGpsuFHHMY4Ak7XNIrv6hm6bzdf9dT2VpFmeC7anxL_VuHe6KrbeV9LsCWLGXW_Ryi4PcYvH4cCj8B6yub78</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2287828402</pqid></control><display><type>article</type><title>Immunoglobulin G4 related disease: a single‐centre experience from South Australia</title><source>Access via Wiley Online Library</source><creator>Pucar, Phillippa A. ; Nolan, James ; Hissaria, Pravin</creator><creatorcontrib>Pucar, Phillippa A. ; Nolan, James ; Hissaria, Pravin</creatorcontrib><description>Background IgG4 related disease (IgG4RD) is a newly described multisystem fibro‐inflammatory disorder. There is a paucity of literature describing the Australian experience of this rare condition. Aims To characterise the Royal Adelaide Hospital IgG4RD cohort with biopsy‐proven disease. Methods A search of the Frome Road SA Pathology database was performed for all tissue biopsies containing the phrase ‘IgG4 positive’. Case notes were reviewed for clinical details, laboratory and radiology results. Histological features according to the Boston Criteria were used. Patients with available case notes, highly suggestive or probable histology and clinical features to suggest IgG4RD were included. Results Twenty patients had definite or probable IgG4RD and suggestive clinical features; median age 59 (20–76), male : female 1.5:1. There was considerable delay in diagnosis (median diagnosis at 64 months). Organ involvement included: 11 exocrine gland, seven pancreatobiliary, seven nodal, seven soft tissue, five retro‐orbital, three retroperitoneal fibrosis and two renal. Systemic symptoms at diagnosis were seen in eight patients. Seven (35%) had an elevated serum IgG4 (&gt;1.35 g/L) at diagnosis. Only 12 (60%) required immunosuppressive treatment (corticosteroids); of these, four (20%) required a steroid‐sparing agent and four (20%) required B‐cell depleting therapy (rituximab). The median duration of follow up was 18 months. Conclusions This is the first characterised Australian cohort with generalised IgG4RD, a rare, relatively indolent and under‐recognised multisystem disorder. Diagnosis is difficult given lack of awareness of this rare condition among physicians, its presentation as a great disease mimic, challenges with histopathological assessment and the absence of a suitable serum biomarker.</description><identifier>ISSN: 1444-0903</identifier><identifier>EISSN: 1445-5994</identifier><identifier>DOI: 10.1111/imj.14331</identifier><language>eng</language><publisher>Melbourne: John Wiley &amp; Sons Australia, Ltd</publisher><subject>Beta cells ; Biopsy ; clinical feature ; Corticosteroids ; Diagnosis ; Exocrine glands ; Fibrosis ; Immunoglobulin G ; Immunoglobulin G4 ; immunoglobulin G4 related disease ; Inflammatory diseases ; Monoclonal antibodies ; pathology ; Patients ; Rituximab ; treatment</subject><ispartof>Internal medicine journal, 2019-09, Vol.49 (9), p.1099-1104</ispartof><rights>2019 Royal Australasian College of Physicians</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-1271-2756</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fimj.14331$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fimj.14331$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids></links><search><creatorcontrib>Pucar, Phillippa A.</creatorcontrib><creatorcontrib>Nolan, James</creatorcontrib><creatorcontrib>Hissaria, Pravin</creatorcontrib><title>Immunoglobulin G4 related disease: a single‐centre experience from South Australia</title><title>Internal medicine journal</title><description>Background IgG4 related disease (IgG4RD) is a newly described multisystem fibro‐inflammatory disorder. There is a paucity of literature describing the Australian experience of this rare condition. Aims To characterise the Royal Adelaide Hospital IgG4RD cohort with biopsy‐proven disease. Methods A search of the Frome Road SA Pathology database was performed for all tissue biopsies containing the phrase ‘IgG4 positive’. Case notes were reviewed for clinical details, laboratory and radiology results. Histological features according to the Boston Criteria were used. Patients with available case notes, highly suggestive or probable histology and clinical features to suggest IgG4RD were included. Results Twenty patients had definite or probable IgG4RD and suggestive clinical features; median age 59 (20–76), male : female 1.5:1. There was considerable delay in diagnosis (median diagnosis at 64 months). Organ involvement included: 11 exocrine gland, seven pancreatobiliary, seven nodal, seven soft tissue, five retro‐orbital, three retroperitoneal fibrosis and two renal. Systemic symptoms at diagnosis were seen in eight patients. Seven (35%) had an elevated serum IgG4 (&gt;1.35 g/L) at diagnosis. Only 12 (60%) required immunosuppressive treatment (corticosteroids); of these, four (20%) required a steroid‐sparing agent and four (20%) required B‐cell depleting therapy (rituximab). The median duration of follow up was 18 months. Conclusions This is the first characterised Australian cohort with generalised IgG4RD, a rare, relatively indolent and under‐recognised multisystem disorder. Diagnosis is difficult given lack of awareness of this rare condition among physicians, its presentation as a great disease mimic, challenges with histopathological assessment and the absence of a suitable serum biomarker.</description><subject>Beta cells</subject><subject>Biopsy</subject><subject>clinical feature</subject><subject>Corticosteroids</subject><subject>Diagnosis</subject><subject>Exocrine glands</subject><subject>Fibrosis</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulin G4</subject><subject>immunoglobulin G4 related disease</subject><subject>Inflammatory diseases</subject><subject>Monoclonal antibodies</subject><subject>pathology</subject><subject>Patients</subject><subject>Rituximab</subject><subject>treatment</subject><issn>1444-0903</issn><issn>1445-5994</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpdkLFOwzAURS0EEqUw8AeWWFjS-sVOk7BVFZSiIgbKHDn2c3HlJMVOBN34BL6RLyEtTLzl3uHo6ukQcglsBP2NbbUZgeAcjsgAhEiiJM_F8aGLiOWMn5KzEDaMQcpzMSCrRVV1dbN2Tdk5W9O5oB6dbFFTbQPKgDdU0mDrtcPvzy-FdeuR4scWvcVaITW-qehz07WvdNqF1ktn5Tk5MdIFvPjLIXm5u13N7qPl03wxmy6jLaQAkVKYgChLBmWsE6W10rnmZmJKmIgyzgXwDFXKWGYyUYrYGAPphJksV9IwLfmQXP_ubn3z1mFoi8oGhc7JGpsuFHHMY4Ak7XNIrv6hm6bzdf9dT2VpFmeC7anxL_VuHe6KrbeV9LsCWLGXW_Ryi4PcYvH4cCj8B6yub78</recordid><startdate>201909</startdate><enddate>201909</enddate><creator>Pucar, Phillippa A.</creator><creator>Nolan, James</creator><creator>Hissaria, Pravin</creator><general>John Wiley &amp; Sons Australia, Ltd</general><general>Wiley Subscription Services, Inc</general><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1271-2756</orcidid></search><sort><creationdate>201909</creationdate><title>Immunoglobulin G4 related disease: a single‐centre experience from South Australia</title><author>Pucar, Phillippa A. ; Nolan, James ; Hissaria, Pravin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p1711-cce514bb01b2d5cddcd9d3f6fb164b294138ec7008f84b42fff1760f89caf0da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Beta cells</topic><topic>Biopsy</topic><topic>clinical feature</topic><topic>Corticosteroids</topic><topic>Diagnosis</topic><topic>Exocrine glands</topic><topic>Fibrosis</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulin G4</topic><topic>immunoglobulin G4 related disease</topic><topic>Inflammatory diseases</topic><topic>Monoclonal antibodies</topic><topic>pathology</topic><topic>Patients</topic><topic>Rituximab</topic><topic>treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pucar, Phillippa A.</creatorcontrib><creatorcontrib>Nolan, James</creatorcontrib><creatorcontrib>Hissaria, Pravin</creatorcontrib><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Internal medicine journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pucar, Phillippa A.</au><au>Nolan, James</au><au>Hissaria, Pravin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunoglobulin G4 related disease: a single‐centre experience from South Australia</atitle><jtitle>Internal medicine journal</jtitle><date>2019-09</date><risdate>2019</risdate><volume>49</volume><issue>9</issue><spage>1099</spage><epage>1104</epage><pages>1099-1104</pages><issn>1444-0903</issn><eissn>1445-5994</eissn><abstract>Background IgG4 related disease (IgG4RD) is a newly described multisystem fibro‐inflammatory disorder. There is a paucity of literature describing the Australian experience of this rare condition. Aims To characterise the Royal Adelaide Hospital IgG4RD cohort with biopsy‐proven disease. Methods A search of the Frome Road SA Pathology database was performed for all tissue biopsies containing the phrase ‘IgG4 positive’. Case notes were reviewed for clinical details, laboratory and radiology results. Histological features according to the Boston Criteria were used. Patients with available case notes, highly suggestive or probable histology and clinical features to suggest IgG4RD were included. Results Twenty patients had definite or probable IgG4RD and suggestive clinical features; median age 59 (20–76), male : female 1.5:1. There was considerable delay in diagnosis (median diagnosis at 64 months). Organ involvement included: 11 exocrine gland, seven pancreatobiliary, seven nodal, seven soft tissue, five retro‐orbital, three retroperitoneal fibrosis and two renal. Systemic symptoms at diagnosis were seen in eight patients. Seven (35%) had an elevated serum IgG4 (&gt;1.35 g/L) at diagnosis. Only 12 (60%) required immunosuppressive treatment (corticosteroids); of these, four (20%) required a steroid‐sparing agent and four (20%) required B‐cell depleting therapy (rituximab). The median duration of follow up was 18 months. Conclusions This is the first characterised Australian cohort with generalised IgG4RD, a rare, relatively indolent and under‐recognised multisystem disorder. Diagnosis is difficult given lack of awareness of this rare condition among physicians, its presentation as a great disease mimic, challenges with histopathological assessment and the absence of a suitable serum biomarker.</abstract><cop>Melbourne</cop><pub>John Wiley &amp; Sons Australia, Ltd</pub><doi>10.1111/imj.14331</doi><tpages>129</tpages><orcidid>https://orcid.org/0000-0002-1271-2756</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1444-0903
ispartof Internal medicine journal, 2019-09, Vol.49 (9), p.1099-1104
issn 1444-0903
1445-5994
language eng
recordid cdi_proquest_miscellaneous_2232115722
source Access via Wiley Online Library
subjects Beta cells
Biopsy
clinical feature
Corticosteroids
Diagnosis
Exocrine glands
Fibrosis
Immunoglobulin G
Immunoglobulin G4
immunoglobulin G4 related disease
Inflammatory diseases
Monoclonal antibodies
pathology
Patients
Rituximab
treatment
title Immunoglobulin G4 related disease: a single‐centre experience from South Australia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T17%3A26%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_wiley&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunoglobulin%20G4%20related%20disease:%20a%20single%E2%80%90centre%20experience%20from%20South%20Australia&rft.jtitle=Internal%20medicine%20journal&rft.au=Pucar,%20Phillippa%20A.&rft.date=2019-09&rft.volume=49&rft.issue=9&rft.spage=1099&rft.epage=1104&rft.pages=1099-1104&rft.issn=1444-0903&rft.eissn=1445-5994&rft_id=info:doi/10.1111/imj.14331&rft_dat=%3Cproquest_wiley%3E2232115722%3C/proquest_wiley%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2287828402&rft_id=info:pmid/&rfr_iscdi=true